Dianthus Therapeutics Inc. (DNTH) earnings · next report Nov 4, 2026
Next report
Wed, Nov 4, 2026
Time not announced · Today
Quarter ended Sep 2026
- EPS consensus
- $1.00 Range −$1.13 – −$0.3910 analystsYear ago −$0.97
- Revenue consensus
- $388.66K Range $0 – $1.00M15 analysts
EPS estimate trend
- 90 days ago−$1.02
- 60 days ago−$1.02
- 30 days ago−$1.02
- 7 days ago−$0.95
- Now−$0.95
Consensus +7.2% over 90 days. Last 30 days: 2 up, 1 down revisions.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow DNTH into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 4)
- ±11.7% Priced at the Nov 3 close · expiry Nov 20 (17 days: includes non-earnings days)
- Average move after earnings
- ±1.1% Absolute close-to-close move, 2 reports
Options expect a bigger move than DNTH’s average after earnings (±11.7% vs ±1.1%).
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.90
vs −$0.93 est. +3.2%
GAAP diluted EPS, SEC 10-Q
Revenue
$11.54M
vs $248.75K est. +4540.0%
As filed with the SEC
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS 2 quarters in a row
- Beat EPS in 2 of 4
- Aug 4, 2026BeatEPS −$0.90GAAP vs −$0.93 +3.2%Rev $11.54M vs $248.75K +4540.0%
- May 5, 2026BeatEPS −$0.85GAAP vs −$1.10 +22.7%Rev $6.26M vs $358.69K +1646.6%
- Nov 5, 2025MissEPS −$0.97GAAP vs −$0.86 −12.8%Rev $396.00K vs $523.64K −24.4%
- Aug 7, 2025MissEPS −$0.88GAAP vs −$0.86 −2.3%Rev $193.00K vs $864.67K −77.7%
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Jun 2026 | −$0.93 | −$0.90GAAP | +3.2% | $248.75K | $11.54MSEC | +4540.0% |
| May 5, 2026 | Mar 2026 | −$1.10 | −$0.85GAAP | +22.7% | $358.69K | $6.26MSEC | +1646.6% |
| Nov 5, 2025 | Sep 2025 | −$0.86 | −$0.97GAAP | −12.8% | $523.64K | $396.00KSEC | −24.4% |
| Aug 7, 2025 | Jun 2025 | −$0.86 | −$0.88GAAP | −2.3% | $864.67K | $193.00KSEC | −77.7% |
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All DNTH filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
DNTH is rated 2.67 of 5 among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- CTEV earnings2.70 · Hold · stock
- DNLI earnings2.70 · Hold · stock
- SYRE earnings2.69 · Hold · stock
- BBNX earnings2.68 · Hold · stock
- SRPT earnings2.67 · Hold · stock
- SI earnings2.66 · Hold · stock
- MRVI earnings2.65 · Hold · stock
- ARVN earnings2.64 · Hold · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | $11.54M | −$0.90 | +5880.3% |
| Q1 FY26 | $6.26M | −$0.85 | +438.7% |
| Q3 FY25 | $396.00K | −$0.97 | −81.8% |
| Q2 FY25 | $193.00K | −$0.88 | −89.6% |
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
Latest reported DNTH revenue for 2025-12-31 was $2.0M. Net income was -$162.3M. Revenue was down 67.3% from 2024-12-31 to 2025-12-31. DNTH currently screens at market cap $4.40B.
When the next DNTH 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was down 67.3% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full DNTH research stays on the stock page; the tape stays on the quote page.
DNTH earnings FAQ
When is DNTH's next earnings date?
Dianthus Therapeutics Inc. (DNTH) is expected to report on Wed, Nov 4, 2026. This is the provider’s estimated date; the company has not confirmed it. Consensus EPS is $1.00.
Did DNTH beat earnings estimates last quarter?
Yes. On Aug 4, 2026 Dianthus Therapeutics Inc. (DNTH) reported adjusted EPS of −$0.90 against a −$0.93 consensus (+3.2%), a beat. It reported revenue $11.54M vs $248.75K est. (+4540.0%).
How often does DNTH beat EPS estimates?
Dianthus Therapeutics Inc. (DNTH) beat the EPS consensus in 3 of its last 8 reported quarters. Revenue beat the consensus in 2 of the last 4 quarters with an estimate on file.
What are DNTH's latest revenue and net income?
Latest cached Dianthus Therapeutics Inc. (DNTH) revenue for Dec 31, 2025 was $2.0M. Net income was -$162.3M. Statements: https://lician.com/financials/dnth
What is DNTH's latest diluted EPS?
Latest cached Dianthus Therapeutics Inc. (DNTH) diluted EPS for Dec 31, 2025 was -$4.20.
What period does the latest DNTH earnings print cover?
The latest cached Dianthus Therapeutics Inc. (DNTH) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
How did DNTH revenue change from the prior cached period?
Cached Dianthus Therapeutics Inc. (DNTH) revenue was down 67.3% from $6.2M (Dec 31, 2024) to $2.0M (Dec 31, 2025). Statements: https://lician.com/financials/dnth
Where are DNTH earnings listed?
Cached earnings facts for Dianthus Therapeutics Inc. (DNTH) are listed at https://lician.com/earnings/dnth. Statements: https://lician.com/financials/dnth
Not investment advice.